Methylation of the neutral endopeptidase gene promoter in human prostate cancers

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1664-1670

  Usmani, Badar A ^a   Shen, Ruoqian ^a   Janeczko, Michael ^a   Papandreou, Christos N ^b   Lee, Wen Hsiang ^c   Nelson, William G ^c   Nelson, Joel B ^c   Nanus, David M ^a,d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE METALLOENDOPEPTIDASE;

ARTICLE; DNA DETERMINATION; DNA METHYLATION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; SOUTHERN BLOTTING; TRANSCRIPTION REGULATION;

AZACITIDINE; DNA METHYLATION; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEPRILYSIN; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0034075990     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Papandreou, C. N., Usmani, B., Geng, Y. P., Bogenrieder, T., Freeman, R. H., Wilk, S., Finstad, C. L., Reuter, V. E., Powell, C. T., Scheinberg, D., Magill, C. Scher, H. I., Albino, A. P., and Nanus, D. M. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat. Med., 4: 50-57, 1998.
2. Jarrard, D. F., Bova, G. S., and Isaacs, W. B. DNA methylation, molecular genetic, and linkage studies in prostate cancer. Prostate, 6 (Suppl.): 36-44, 1996.
3. Graff, J. R., Herman, J. G., Lapidus, R. G., Chopra, H., Xu, R., Jarrard, D. F., Isaacs, W. B., Pitha, P. M., Davidson, N. E., and Baylin, S. B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res., 55: 5195-5199, 1995.
4. Jarrard, D. F., Bova, G. S., Ewing, C. M., Pin, S. S., Nguyen, S. H., Baylin, S. B., Cairns, P., Sidransky, D., Herman, J. G., and Isaacs, W. B. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer, 19: 90-96, 1997.
5. Nelson, J. B., Lee, W. H., Nguyen, S. H., Jarrard, D. F., Brooks, J. D., Magnuson, S. R., Opgenorth, T. J., Nelson, W. G., and Bova, G. S. Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res., 57: 35-37, 1997.
6. D'Adamio, L., Shipp, M. A., Masteller, E. L., and Reinherz, E. L. Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): multiple miniexons and separate 5′ untranslated regions. Proc. Natl. Acad. Sci. USA, 86: 7103-7107, 1989.
7. Ishimaru, F., and Shipp, M. A. Analysis of the human CD10/neutral endopeptidase 24.11 promotor region: two separate regulatory elements. Blood, 85: 3199-3207, 1995.
8. Papandreou, C. N., Bogenrieder, T., Scher, H. I., Albino, A. P., and Nanus, D. M. Expression and sequence analysis of the SD11/WAF1/CIP1/p21 tumor suppressor gene in prostate cancer cell lines. Int. J. Oncol., 8: 1237-1241, 1996.
9. Ohya, K., Okada, H., Gotoh, A., Hara, I., Fujisawa, M., Gohji, K., Arakawa, S., and Kamidono, S. A unique cell line derived from a small cell carcinoma of the prostate. J. Urol., 157: 223, 1997.
10. Nelson, J. B., Chantack, K., Hedican, S. P., Magnuson, S. R., Opgenorth, T. J., Bova, G. S., and Simons, J. W. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res., 56: 663-668, 1996.
11. Albino, A. P., Davis, B. M., and Nanus, D. M. Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. Cancer Res., 51: 4815-4820, 1991.
12. Hoffman, A. D., Engelstein, D., Steckelman, E., Bogenrieder, T., Dave, A., Papandreou, C. N., Motzer, R. J., Albino, A. P., and Nanus, D. M. Expression of retinoic acid receptor β in human renal cell carcinomas correlates with sensitivity to the antiproliferative effect of 13-cis retinoic acid. Clin. Cancer Res., 2: 1077-1082, 1996.
13. Gussow, D., Rein, R., Ginjaar, I., Hochstenbach, F., Seemann, G., Kottman, A., and Ploegh, H. L. The human β2-microglobulin gene. J. Immunol., 139: 3132-3138, 1987.
14. Ishimaru, F., Mari, B., and Shipp, M. A. The type 2 CD10/neutral endopeptidase 24.11 promoter: functional characterization and tissue-specific regulation by CBF/NF-Y isoforms. Blood, 89: 4136-4145, 1997.
15. Krongrad, A., Atochina, E., Ryan, J. W., and Roos, B. A. Endopeptidase 24.11 activity in the human prostate cancer cell lines LNCaP and PPC-1. Urol. Res., 25: 113-116, 1997.
16. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR. A novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
17. Graff, J. R., Herman, J. G., Myohanen, S., Baylin, S. B., and Vertino, P. M. Mapping patterns of CpG island methylation in normal and neoplastic cells implicate both upstream and downstream regions in de novo methylation. J. Biol. Chem., 272: 22322-22329, 1997.
18. Jarrard, D. F., Kinoshita, H., Shi, Y., Sandefur, C., Hoff, D., Meisner, L. F., Chang, C., Herman, J. G., Isaacs, W. B., and Nassif, N. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res., 58: 5310-5314, 1998.
19. Wainstein, M. A., He, F., Robinson, D., Kung, H. J., Schwartz, S., Giaconia, J. M., Edgehouse, N. L., Pretlow, T. P., Bodner, D. R., Kursh, E. D., Resnick, M. I., Seftel, A., and Pretlow, T. G. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res., 54: 6049-6052, 1994.
20. Nagabhushan, M., Miller, C. M., Pretlow, T. P., Giaconia, J. M., Edgehouse, N. L., Schwartz, S., Kung, H. J., de Vere White, R. W., Gumerlock, P. H., Resnick, M. I., Amini, S. B., and Pretlow, T. G. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res., 56: 3042-3046, 1996.
21. Agus, D. B., Golde, D. W., Sgouros, G., Ballangrud, A., Cordon-Cardo, C., and Scher, H. I. Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res., 58: 3009-3014, 1998.
22. Shen, R., Sumitomo, M., Dai, J., Harris, A., Kaminetzky, D., Gao, M., Bumstein, K., and Nanus, D. M. Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology, in press, 2000.
23. Selbie, L. A., and Hill, S. J. G protein-coupled-receptor cross-talk: the fine-tuning of multiple receptor-signalling pathways. Trends Pharmacol. Sci., 19: 87-93, 1998.
24. Baylin, S. B., Herman, J. G., Graff, J. R., Vertino, P. M., and Issa, J. P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res., 72: 141-196, 1998.
25. Letarte, M., Greaves, A., and Ishii, E. The biological functions of CD10/endopeptidase-24.11 in normal and malignant cells. In: A. J. Kenny and C. M. Boustead (eds.), Cell-Surface Peptidases in Health and Disease, pp. 329-339. Oxford. United Kingdom: BIOS Scientific Publishers Ltd., 1997.
26. Lu, S., Tsai, S. Y., and Tsai, M. J. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res., 57: 4511-4516, 1997.
27. Di Sant'Agnese, P. A. Neuroendocrine differentiation in prostatic carcinoma. Cancer (Phila.), 75: 1850-1859, 1995.
28. Aprikian, A. G., Han, K., Guy, L., Landry, F., Begin, L. R., and Chevalier, S. Neuroendocrine differentiation and the bombesin/gastrin releasing peptide family of neuropeptides in the progression of human prostate cancer. Prostate. 8: 52-61, 1998.